International Pharmaceutical Abstracts 1994: Vol 31 Index

695 Pages·1994·264.3 MB·English

G
AUTHOR INDEX—The Author Index is published semi-annually as part of the June 30th and December 30th issues. Authors are
listed alphabetically by last name except for sisters of religious orders who are listed under “Sister” followed by their name. The
title of the abstract is given after the principal author entry. “See” references to the principal author are given after secondary
U author entries.
SUBJECT INDEX—A cumulative subject indexi sp ublished semi-annually as part of the June 30th and December 30th issues and represents
accumulation of the subject indexes published as part of the preceding 11 semi-monthly abstract issues.
I
Whenever possible, drugs are indexed under nonproprietary names adopted by the United States Adopted Names (USAN).
Chemical substances are indexed under the complete chemical name. However, they are ized under the major chemical name,
not the minor prefix. For example, 1-h-D-arabinofuranosylcytosine is alphabetized under “A.” Trade names and numbers of compounds
D have also been indexed when mentioned in the abstract, usually with a reference to the nonproprietary or chemical name. If an entry consists
only of numbers, it appears at the beginning of the index.
Concepts are also indexed and, depending on the emphasis in an abstract, index entries describing the disease treated and a drug’s
pharmacologic activity are included. Toxic or adverse reactions caused by a drug are also indexed.
3)
The subject headings listed below may be used as a guide in utilizing the index. Reference numbers to abstracts appearing in each
of the twenty-five sections of International Pharmaceutical Abstracts (see below) will be found under that subject heading in the index.
A “see also” reference number is given for those abstracts appearing in one section that have pertinent information relating to another
section, i.e., an abstract on structure-activity might appear in the section on Pharmaceutical Chemistry if chemistry were emphasized,
but a “see also” reference number under the Pharmacology index entry would locate the abstract for those interested in that aspect.
“See” references are given for individual index entries when such entries make the index easier to use, i.e., Drug Stability, see Stability.
a The following is a list of all sections published in International Pharmaceutical Abstracts with a brief description of the abstracts
appearing in each section and illustrations of typical and atypical topics:
O
Adverse Drug Reactions Environmental Toxicity
Abstracts are included that discuss a reaction not ex- Abstracts are included that discuss toxicity due to human or
pected or intended when a medication is given in the normal animal environment or contact, e.g., occupational drug poison-
dose range and route of administration, e.g., reactions not ing, pharmaceutical chemicals, zoonoses, pollutants, hospital
normally listed as side effects, unexpected drug addiction, acquired infections, etc.
hypersensitivity, potentiation of dormant or other disease
U State, etc. History
Abstracts are included that discuss the history of all phases
Bi of pharmacy and drug use, including modem history, e.g., history
Abstracts are included that discuss the effect of formu- of the law of pharmacy, drug discoveries, pharmacy practice,
S lation, physical-chemical properties, particle size and dosage pharmacy literature and art, etc.
form on the body or tissue, e.g., pharmacokinetic studies, in
vivo dissociation time studies, absorption and adsorption, Information Processing and Literature
E effect of sustained-action medications, generic and therapeu- Abstracts are included that discuss drug literature and infor-
tic equivalency, bioavailability, drug-complex effects, effects mation and its use, e.g., data processing, new book and joumal
of different salts or esters, effect of route of administration on references, pharmacopeias, drug information systems, automated
action if dosage-form related, etc. record keeping, nomenclature, information transfer, etc.
Drug Analysis Institutional Pharmacy Practice
Abstracts are included that discuss an assay or analysis in Abstracts are included that discuss institutional pharmacy
which a drug or drugs are quantitatively or qualitatively tested, practice, e.g., hospitals, extended care facilities, nursing homes,
O e.g., content, impurities, counterfeit drugs, etc. long-term care facilities, skilled nursing facilities, mental health
facilities, administrative control, hospital administration, drug
Drug Evaluations distribution systems, pharmacist’s role in compounding paren-
Abstracts are included that discuss the therapy or specific
K teral solutions, patient care, outpatient pharmacy services, etc.
in vivo effect of an established (noninvestigational or experi-
mental) drug in prophylaxis, treatment, diagnosis, ora disease Investigational Drugs
State, e.g., Clinical cases, dosage amount comparison study,
Abstracts are included that discuss the action in a human of
resistance, tolerance, placebo effects, etc.
a drug that is investigational or not currently used in the United
States, e.g., drugs may be included that are not investigational in
Drug Interactions
countries other than the United States, clinical trials, double-blind
Abstracts are included that discuss an in vivo drug-dmug,
studies, etc.
drug-chemical, or drug-food interaction relating to therapy or
diagnosis (includes interaction of drug and radiation therapy)
e.g., synergism, summation, potentiation, antagonism, com- Legislation, Laws and Regulations
Abstracts are included that discuss legislation, standards and
petition, in vivo drug-complex formation, etc.
regulations, e.g., patents, narcotic and dangerous drug regulations,
Drug Metabolism and Body Distribution licensure, accreditation, taxation, drug recalls, liability cases, etc.
Abstracts are included that discuss the actual metabolism
of a drug or distribution of a drug in the body, e.g., pharmaco- Methodol
kinetics, absorption, adsorption, excretion, endogenous physi- Abstracts are included that discuss means and methods of
ologic interaction, biotransformation, test or analysis of drugs evaluating a drug action in humans, animals, or biological systems,
in body fluids or tissue, placental barrier and transfer, drugs e.g., Clinical study design, equipment, systems, procedures, etc.
present in lactation, effect of route of administration on drug’s
availability and breakdown, etc. Microbiology
Abstracts are included that discuss pharmaceuticals, their
Drug Stability effect on or preparation from microorganisms, and microbiology
Abstracts are included that discuss decomposition of a important to pharmacy, e.g., effect of a medication on an
specific pharmaceutical or drug and in vitro incompatibilities, organism in vitro, resistance studies, in vitro antibiotic spectrum
cKeM e.gO., hydrolZysis, eTffects o f temperature, effects due to con- studies, effect of environmental conditions on micro-organisms,
tainer, moisture, parenteral admixture incompatibilities, etc. etc.
G
AUTHOR INDEX—The Author Index is published semi-annually as part of the June 30th and December 30th issues. Authors are
listed alphabetically by last name except for sisters of religious orders who are listed under “Sister” followed by their name. The
title of the abstract is given after the principal author entry. “See” references to the principal author are given after secondary
U author entries.
SUBJECT INDEX—A cumulative subject indexi sp ublished semi-annually as part of the June 30th and December 30th issues and represents
accumulation of the subject indexes published as part of the preceding 11 semi-monthly abstract issues.
I
Whenever possible, drugs are indexed under nonproprietary names adopted by the United States Adopted Names (USAN).
Chemical substances are indexed under the complete chemical name. However, they are ized under the major chemical name,
not the minor prefix. For example, 1-h-D-arabinofuranosylcytosine is alphabetized under “A.” Trade names and numbers of compounds
D have also been indexed when mentioned in the abstract, usually with a reference to the nonproprietary or chemical name. If an entry consists
only of numbers, it appears at the beginning of the index.
Concepts are also indexed and, depending on the emphasis in an abstract, index entries describing the disease treated and a drug’s
pharmacologic activity are included. Toxic or adverse reactions caused by a drug are also indexed.
3)
The subject headings listed below may be used as a guide in utilizing the index. Reference numbers to abstracts appearing in each
of the twenty-five sections of International Pharmaceutical Abstracts (see below) will be found under that subject heading in the index.
A “see also” reference number is given for those abstracts appearing in one section that have pertinent information relating to another
section, i.e., an abstract on structure-activity might appear in the section on Pharmaceutical Chemistry if chemistry were emphasized,
but a “see also” reference number under the Pharmacology index entry would locate the abstract for those interested in that aspect.
“See” references are given for individual index entries when such entries make the index easier to use, i.e., Drug Stability, see Stability.
a The following is a list of all sections published in International Pharmaceutical Abstracts with a brief description of the abstracts
appearing in each section and illustrations of typical and atypical topics:
O
Adverse Drug Reactions Environmental Toxicity
Abstracts are included that discuss a reaction not ex- Abstracts are included that discuss toxicity due to human or
pected or intended when a medication is given in the normal animal environment or contact, e.g., occupational drug poison-
dose range and route of administration, e.g., reactions not ing, pharmaceutical chemicals, zoonoses, pollutants, hospital
normally listed as side effects, unexpected drug addiction, acquired infections, etc.
hypersensitivity, potentiation of dormant or other disease
U State, etc. History
Abstracts are included that discuss the history of all phases
Bi of pharmacy and drug use, including modem history, e.g., history
Abstracts are included that discuss the effect of formu- of the law of pharmacy, drug discoveries, pharmacy practice,
S lation, physical-chemical properties, particle size and dosage pharmacy literature and art, etc.
form on the body or tissue, e.g., pharmacokinetic studies, in
vivo dissociation time studies, absorption and adsorption, Information Processing and Literature
E effect of sustained-action medications, generic and therapeu- Abstracts are included that discuss drug literature and infor-
tic equivalency, bioavailability, drug-complex effects, effects mation and its use, e.g., data processing, new book and joumal
of different salts or esters, effect of route of administration on references, pharmacopeias, drug information systems, automated
action if dosage-form related, etc. record keeping, nomenclature, information transfer, etc.
Drug Analysis Institutional Pharmacy Practice
Abstracts are included that discuss an assay or analysis in Abstracts are included that discuss institutional pharmacy
which a drug or drugs are quantitatively or qualitatively tested, practice, e.g., hospitals, extended care facilities, nursing homes,
O e.g., content, impurities, counterfeit drugs, etc. long-term care facilities, skilled nursing facilities, mental health
facilities, administrative control, hospital administration, drug
Drug Evaluations distribution systems, pharmacist’s role in compounding paren-
Abstracts are included that discuss the therapy or specific
K teral solutions, patient care, outpatient pharmacy services, etc.
in vivo effect of an established (noninvestigational or experi-
mental) drug in prophylaxis, treatment, diagnosis, ora disease Investigational Drugs
State, e.g., Clinical cases, dosage amount comparison study,
Abstracts are included that discuss the action in a human of
resistance, tolerance, placebo effects, etc.
a drug that is investigational or not currently used in the United
States, e.g., drugs may be included that are not investigational in
Drug Interactions
countries other than the United States, clinical trials, double-blind
Abstracts are included that discuss an in vivo drug-dmug,
studies, etc.
drug-chemical, or drug-food interaction relating to therapy or
diagnosis (includes interaction of drug and radiation therapy)
e.g., synergism, summation, potentiation, antagonism, com- Legislation, Laws and Regulations
Abstracts are included that discuss legislation, standards and
petition, in vivo drug-complex formation, etc.
regulations, e.g., patents, narcotic and dangerous drug regulations,
Drug Metabolism and Body Distribution licensure, accreditation, taxation, drug recalls, liability cases, etc.
Abstracts are included that discuss the actual metabolism
of a drug or distribution of a drug in the body, e.g., pharmaco- Methodol
kinetics, absorption, adsorption, excretion, endogenous physi- Abstracts are included that discuss means and methods of
ologic interaction, biotransformation, test or analysis of drugs evaluating a drug action in humans, animals, or biological systems,
in body fluids or tissue, placental barrier and transfer, drugs e.g., Clinical study design, equipment, systems, procedures, etc.
present in lactation, effect of route of administration on drug’s
availability and breakdown, etc. Microbiology
Abstracts are included that discuss pharmaceuticals, their
Drug Stability effect on or preparation from microorganisms, and microbiology
Abstracts are included that discuss decomposition of a important to pharmacy, e.g., effect of a medication on an
specific pharmaceutical or drug and in vitro incompatibilities, organism in vitro, resistance studies, in vitro antibiotic spectrum
cKeM e.gO., hydrolZysis, eTffects o f temperature, effects due to con- studies, effect of environmental conditions on micro-organisms,
tainer, moisture, parenteral admixture incompatibilities, etc. etc.
Pharmaceutical Chemistry Pharmacology
Abstracts are included that discuss chemistry, e.g., synthesis, Abstracts are included that discuss the mode or mechanism of
structure-activity, separation and purification, structure determina- action or a general discussion of a drug or diagnostic agent that is not
tions, pure analytical chemistry, etc. a clinical evaluation, e.g., establishing the biological activity of newly
synthesized chemicals, activity due to structural differences, site of
Pharmaceutical Education action determinations, route of administration determinations, drug-
Abstracts are included that discuss education and training relating disease discussions, pharmacogenetics, biochemistry, drug screening,
to pharmacy, e.g., residency programs, technician training, continuing establishing dosage and dosage schedules, etc.
education, academic education, pharmaceutical research, etc.
Pharmacy Practice
Abstracts are included that discuss pharmacy in general, e.g.,
Pharmaceutical Technology pharmacy design, dispensing, professional practice, pharmacist’s role
Abstracts are included that discuss manufacturing, formulas and in the community, over-the-counter drugs, home health care agencies,
formulations of pharmaceuticals, sterilization and contamination, first aid supplies, labeling, prescriptions, compounding technique, etc.
routine tests on pharmaceutical preparations, plastics and packaging
and numerous other topics of a similar nature, e.g., dosage forms, Preliminary Drug Testing
distillations, preparation of parenterals, aseptic technique, aerosols, Abstracts are included that discuss an established action in an
containers, preservatives, pyrogens, quality control, flavoring, specific animal of an experimental drug still in the investigational or pre-
preparation processes, antibiotic manufacturing, equipment, closures, investigational stage, e.g., animal studies on new uses for established
granulation, powder flow studies, vehicles, hardness and disintegration drugs, antimicrobial studies in animals, tissue cultures, etc.
tests, etc.
Sociology, Economics and Ethics
Pharmaceutics Abstracts are included that discuss the effects of drugs, pharinacy,
Abstracts are included that discuss physical pharmacy or chemis- pharmaceutical practice, or medicine on society and the economics and/
try, theology, nonroutine tests on pharmaceutical preparations, e.g., or ethics involved in pharmacy, e.g., cost surveys, reimbursement,
marketing, error studies, pharmacists’ civic duties, effect of disease on
dissolution, filtration, pH studies, dissociation constant determinations,
surface action studies, ionization, isotonicity, micelles, crystallization, society, epidemics and eradication, addiction and habituation, drug
oveiuse and abuse, health care and plans, disaster preparedness, etc.
complex formation, emulsion creaming and breaking, solubility, etc.
Toxicity
Abstracts are included that discuss toxicity, toxicology, poisoning,
Abstracts are included that discuss the isolation, extraction, lethal dose studies of a drug or chemical, e.g., addiction, teratogenicity,
growth, etc., of plants producing drugs or drug products, e.g., separation, habituation, withdrawal, side effects, results of drug overuse and abuse,
biosynthesis of plant products, fungus and fungicides, algae, yeasts, etc. antidotes, contraindications, overdose, etc.
The following alphabetical list of topics that may appear in varied sections, depending on the article’s emphasis, is included for your convenience:
Additives Control Health maintenance organizations Peer review
Adjuncts Cosmetics Home health care Personnel
Adulteration Devices Hyperalimentation Productivity
Advertising Diagnosis related groups Kinetics Purchasing
Ambulatory care Dialysis Lyophilization Quality assurance
Automation Disinfectants Managed care systems Radiopharmaceuticals
Biologicals Drug administration Manpower Safety
Biosynthesis Equipment Materials management Unit-dose
Collective bargaining Folk medicine Medication errors Utilization review
Contamination Health centers Nutrition
HOWTOUSE
To locate information specifically of interest to you:
Each abstracti nJ PA has its own unique number that is a7 digitnumber, e.g.,
3002146. The first 2 digits of this number represent the JPA volume. This —look up the subject of that information in the Subject Index
number is used for reference in both the subject and author indexes.
—if there are multiple entries, determine the abstracts of specific interest
Subject index entries are 3 level entries. The primary level is in bold to you
face type and states the major concept in that entry; the secondary part
of the entry further describes the concept. The primary and secondary —use the unique reference number (the 7-digit number) to find the
entries are consistent standardized entries and are used in both manual abstract in the JPA issue
and computer searching of information in the IPA Information System;
the tertiary entries are used to further describe each index concept so —tead the abstract to determine if this is the kind of information that
that the manual user of the index can easily determine which abstract you really want and note whether the original article is in a language
is of interest. Cross-reference entries are also included to help the user that you can read
locate the precise entry of interest.
— if it is, go to the original article in the primary journal (If the abstract
The author index includes the precise entries to the primary author of citation showed that the article was in “Am. J. Hosp. Pharm.
the article, with cross-references to 4 additional authors of the article. 49:2236-2245 (Sep) 1992,” this indicates volume 49 (year 1992),
the September issue of the American Journal of Hospital Phar-
Each abstract citation includes the original article title, the authors of macy, with the article beginning on page 2236)
the article, the study and reprint address (whenever available), editorial
notes relating to any specific characteristics of the article (“Editorial,” —1the number of references listed indicates those cited with the original
“Letters,” etc.), and the abbreviation and issue information of the article and should lead to even further information on the subject
primary journal in which the article was published. of interest.

Index to Volume Thirty-One
INTERNATIONAL PHARMACEUTICAL ABSTRACTS
January 15, 1994 — June 30, 1994
15 Jan 3100—0 30100056 0 15 Mar 3102—3 39103201 0 15 May 3104835 — 3105365
30 Jan 3100561 — 3101197 30 Mar 3103011 — 3103598 30 May 3105366 — 3106017
15 Feb 3101198 — 3101790 15 Apr 3103—5 39104921 5 15 Jun 3106018 — 3106589
30 Feb 3101791 — 3102391 30 Apr 3104—2 31104683 4 30 Jun CUMULATIVE INDEX
SUBJECT INDEX
Numbers pediatrics, curriculum, 3103542 misoprostol; Brazil, 3103753; utilization, Brazil,
pharmaceutical care, 3103501 3102550, 3102551
pharmaceutical care case studies, 3103514 prostaglandins and mifepristone; efficacy,
589C80, see Tucaresol pharmaceutical care curriculum, 3103538 3101907
pharmaceutical education, outcome measurement, Abruptio placentae; aspirin; toxicity, pre-
3103447 eclampsia prophylaxis, pregnancy, 3100671
pharmaceutics education, 3103547
pharmaceutics, pharmacokinetics education, Abscess; amphotericin B; fungal, brain, local
3103565 therapy, 3101957
A pharmacists consultant education, 3103507 Absorption
pharmacists educational outcomes, 3103499 acetaminophen; interactions, salicylamide,
pharmacy practice curriculum, 3103513, 3103544 metabolism, rats, 3100187; vegetarianism,
A-56268, see Clarithromycin pharmacy services, health assessment, 3103548 3103991
A-74932; synthesis; antineoplastic effects, in vitro, pharmacy students, course evaluation, 3103508 acitretin; percutaneous, methodology, 3104042
3102217 pharmacy students performance prediction, acyclovir; herpes simplex therapy, models,
AACP, see American Association of Colleges of 3103449 3106450
Pharmacy pharmacy students, professional commitment, adinazolam mesylate; rats, dogs, 3106208
AACP meeting abstracts 3103451 albendazole; intestinal, surfactants, rats, 3100731
acquired immunodeficiency syndrome education, postgraduate education, pharmacists careers, alprazolam; pharmacokinetics, postmarketing
3103496 3103517 surveillance applications, 3101605
administration, pharmaceuticai education, 3103540 productivity models, 3103450 aluminum; interactions, sodium silicate, blood
alternative medicine, pharmaceutical education, professional fees, consumers attitudes, 3103489 levels, 3100183
3103558 research curriculum, 3103500, 3103550 aminoglycosides, 3106368
ambulatory care, 3103498 sodium alginate beads, encapsulation, 3103131 ampicillin; continuous ambulatory peritoneal
ambulatory care, continuing education, 3103541 sterile products education, 3103527 dialysis, 3100949
anabolic steroids, athletes, 3103488 teaching strategies, 3103504, 3103528, 3103529, anticonvulsants; pregnancy, epilepsy therapy,
calculations, pharmacy students, 3103555 3103530, 3103531, 3103554 3100818
clerkships, medical missions, 3103537 technology, 3103595 anti-infective agents; mycobacterium infections,
clinical curriculum evaluation, survey, 3103497 U-50488, pregnancy, rats, 3103233 overview, 3104571
communicable diseases, 3103546 visual aids, medicinal chemistry, 3103563 apigenin; extracts, M. recutita, 3103423
communication, 3103522, 3103532, 3103533, women pharmacists, 3103576 apigenin 7-glucoside; extracts, M. recutita,
3103545, 3103557, 3103564 women pharmacists careers, 3103570 3103423
community outreach programs, 3103523 workshops, pharmacy students, 3103566 ascorbic acid; dosage, availability,
community pharmacy clerkships, 3103511, Abbolipid, see Safflower oil; combination, pharmacokinetic models, 3103452
3103516, 3103518, 3103551 soybean oil aspartic acid; percutaneous, in vitro, 3104369
community pharmacy services, 3103573 Abbreviations; prescriptions; nomenclature aspirin, 3104702; immediate release tablets,
community service, 3103505 similarities, error prevention, 3100477 3105574; interactions, cyclosporine, 3100718;
community volunteers, training programs, Abnormalities; acyclovir; teratogenicity, 3102457 microcapsules, rabbits, 3103799
3103552 Abortifacients beta blockers; rabbit intestines, 3102832
computer assisted learning, 3103587 abortion; France, 3101909 budesonide; interactions, charcoal, inhalers,
computers, 3103586, 3103593 carboprost, comparison, dinoprostone; second 3103992
continuing education articles, 3103589 trimester abortion, 3106171 bunazosin hydrochloride; food effects, 3102007;
contraceptive consultation, pharmacy students, dinoprost, comparison, dinoprostone; midtrimester pharmacokinetics, 3100938
3103490 abortion, 3101989 butorphanol tartrate; dosage forms, administration
curriculum revision, 3103509, 3103561 dinoprostone, comparison, carboprost; second routes, availability, 3103113
demographics, pharmacy students, 3103559 trimester abortion, 3106171 calcitonin; transdermal, hydrogels, iontophoresis,
drug literature evaluation, 3103588 dinoprostone, comparison, dinoprost; midtrimester 3101424
drug utilization evaluation, pharmacy schools, abortion, 3101989 captopril; percutaneous, films, gels, 3105579
3103556 gemeprost and mifepristone; comparison, vacuum carbamazepine; complexes, dogs, 3106214;
drug utilization review, community pharmacists, aspiration, abortion, 3100122; dosage, abortion, interactions, vigabatrin, rats, 3102005
3103575 3100128; patients attitudes, 3105454 carebastine; pediatrics, 3103429
education, pharmaceutical, 3103525, 3103543, Harungana madagascariensis; effects, rats, cefdinir; interactions, iron, 3106187
3103553, 3103560, 3103596 3100844 cefetamet pivoxil; review, 3105453
educational outcome models, 3103448 mifepristone; alone and with prostaglandins, cephalexin; comparison, penicillin G, intestinal
GRATEFUL MED, 3103591 therapy, 3101907; and metabolites, transport mechanisms, rabbits, 3106435
handicapped students, 3103503 pharmacokinetics, 3102255; chemistry, chemicals; dermal, equations, 3106464
HIV infections, pharmaceutical education, mechanism of action, 3105449; ovarian function chloroquine sulfate; interactions, cimetidine,
3103524 effects, 3105457 3100719
ibuprofen self-medication, 3103083 mifepristone and gemeprost; comparison, vacuum CI-976; LC, rats, 3105794
immunization, 3103526 aspiration, abortion, 3100122; dosage, abortion, ciprofloxacin; generic equivalency, 3103797
international pharmacy student exchange 3100128; patients attitudes, 3105454 ciprofloxacin hydrochloride; nasal, rats, 3102019
programs, 3103521 misoprostol; utilization, Brazil, 3102550, 3102551 clentiazem maleate; oral, IV, pharmacokinetics,
Internet, 3103592 Abortion 3103430
intravenous therapy education, 3103535 abortifacients; France, 3101909 colony stimulating factor; nasal, rats, 3103789
job performance, examinations, 3103506, acyclovir; teratogenicity, 3102457 cromolyn sodium; pulmonary, structure, crystals,
3103512, 3103519 caffeine; oe 3102444; toxicity, dosage, 3100592
job satisfaction, 3103534 310244: cyanamide; dosage, inhibition, ALDH isozymes,
joint degree programs, 3103502 calagen, comparison, dinoprostone; second rats, 3103225
knowledge maps, 3103536 trimester, 3106171 cyclosporine; chocolate wafer vs solution,
literature evaluation programs, 3103520, 3103594 dinoprost, comparison, dinoprostone; midtrimester, pediatrics, 3105565; formulations, equivalency,
managed care systems clerkships, 3103515 3101989 3104391; interactions, aspirin, 3100718;
Medicaid formularies, 3103492 dinoprostone, comparison, carboprost; second percutaneous, liposomes, mouse skin, 3101432;
Medicaid prior authorization, 3103073 trimester, 3106171 pharmacokinetics, cystic fibrosis, Eisenmenger
medication errors, reports, 3103562 dinoprostone, comparison, dinoprost; midtrimester, complex, 3101609; pharmacokinetics, review,
neoplasm therapy, methodology, 3103453 3101989 3100941
newspapers, 3103597 gemeprost and mifepristone; comparison, vacuum dextrose, comparison, mannitol; effects, intestinal
nontraditional Doctor of Pharmacy, 3103510, aspiration, 3100122; dosage, 3100128; patients permeability, 3102104
3103549 attitudes, 3105454 diclofenac sodium, combination, sucralfate;
nutrition information, 3103571 mifepristone; alone and with prostaglandins, release, tablets, 3106215
nutrition, pharmacists education, 3103572 3101907; review, 3105449 didanosine; colorectal, availability, rats, 3101599;
online databases, pharmacy schools, 3103590 mifepristone and gemeprost; comparison, vacuum interactions, food, chewable tablets, 3100716
patient consultation, OTCs, 3103539 aspiration, 3100122; dosage, 3100128; patients diltiazem; sustained-action, pharmacokinetics,
patient education, diabetes mellitus, 3103574 attitudes, 3105454 models, 3101624
International Pharmaceutical Abstracts 1069
Absorption Subject Index
diltiazem hydrochloride; complexes, nicotinic acid benzyl ester; percutaneous, urofollitropin; IM, men vs women, 3101555
cyclodextrin, vs release, 3102035; sustained- ultrasound effects, 3105567 valproate sodium, combination, valproic acid;
action, 3102814 nifedipine; sustained-action, young vs geriatrics, interactions, food, 3103783
dolasetron mesylate; single dose 3100212 vancomycin; colonic, enterocolitis, 3100355
pharmacokinetics, metabolites, 3102262 nitrofurantoin; availability, dosage forms, vasopressin; transdermal, hydrogels, iontophoresis,
doxazosin; food effects, 3102583 3100201; availability, w/o/w emulsions, 3100733 3101424
drugs; availability, 3102597; colon, dosage forms, nitroglycerin; transdermal patches, methodology, venoms; percutaneous, toads, 3103432
review, 3100203; effects, anesthetics, rats, 3104067 verapamil hydrochloride; percutaneous,
3in1t0r4a0l0i5p;o maetfofuesct,s , 31I0M0,3 5i2D;, smuobdceultsa,n eomuest,h odology, opvafeernvoileowl,; 3b1il0e4 0s0al3t effects, rats, 3104004; oral, IV, vim3no1bnl0ao1st6te0irn4pe e; netsr,a nspmoordte,l s,C ac3o1-024 6c8e0ll s, kinetics,
w3e1i0g6h4t5,1 ;3 1n0a2s0a1l,3 ; ennheaonncaetress,, epfafteecntts, dmuocltuesc ular paprhtiacrlmeasc; okmiincertoi-c, s,p hargatosc,y t3o1s0i1s,6 033 106233 water; povidone mixtures, molecular mobility,
acrhtaenrgieoss,u s 3e1f0f0ec3t5s4,; 31ov0e3r4v2i2e;w , ob3es1i0t3y9,8 5m;a lnutrition, petnriacnislploirnt Gm; ecchoamnpiasrimsso,n , rabcbeipthsa,l e3xi1n0,6 43i5nt estinal c3o1a0t3i8n2g5s,; 3t1ab0l4e4ts0,9 superdisintegrants, aqueous
percutaneous, 3104002; percutaneous, in vitro, peptides; dosage forms, 3106238; nasal, review, zi3d1o0v2u5di9n3e ; percutaneous, phonophoresis,
pH, 3104379; persorption, Gl, in vitro, in vivo, 3103934; oral, formulations, 3100737 Absorption enhancers
3m1e0t0h9o5d0o;l ogpyh,a r3m1a0c6o3d0y8n;a mipcrosp,y lemnoed elgsl,y col phneenoonbaatrebsi,t al3;1 06i4n 3v3i tro percutaneous, mice, ac3id1s0,6 2f1a0tt y; ketoprofen percutaneous absorption,
dicaprylate/dicaprate-ethy! alcohol, 3103118; phenylephrine; pharmacokinetics, review, 3104642 alcohols, ethyl; alone and with propylene glycol
pulsatile dosage forms, 3102600; rectal, dosage phenylpropanolamine; pharmacokinetics, review, dicaprylate/dicaprate, 3103118; interactions, (+)-
forms, 3106206; transdermal, urea vehicle, 3104642 limonene, indomethacin, 3106201; levonorgestrel
3103943; vaginal drug release systems, review, phenylpropanolamine hydrochloride; sustained- permeation, mouse skin, 3102587
3106226 action tablets, 3103129 alcohols, ethyl and menthol; morphine
estradiol; transdermal, lipid effects, 3103128 phenytoin; capsules, oral availability, percutaneous absorption, in vitro, 3105572
estradiol, combination, levonorgestrel; methodology, 3106462; interactions, vigabatrin, aprotinin; toxicity, rat tracheal cilia, 3103038
percutaneous, transdermal patches, 3106205 rats, 3102005 dimethyl-B-cyclodextrin; nasal absorption, insulin,
estriol; percutaneous, creams, 3100372 phytonadione; oral vs parenteral, 3106123 rabbits, rabbits. 3101427
etehfyflec-t4s-,b iBp-hceyncylloadceexttirci nsa,ci d;r atsr,e ct3a1l 02a0va2i1l ability, ppoilryo(xbiuctayml; cpyearncouatcarnyeloautse,) ; genlasn,o ppairgtsi,c l3es1,0 3796 dosdoetcayllo!l Nt,raNn-sddiemrematlh ylpaemrimenaot ioance,t atieo;n toefpfheocrtess,i s,
eextcoidpoileanct;s ; stapbhialritmya,c eduitsiscoalult ioinn,d us3t1ry0,3 79s1el ection, priendtensitmiunaslt,i nei;n victarnoc,e r3 1c0e2ll5s9,8 fibroblasts, do3s1a0g0e1 9f3o rms; oral, availability, review, 3106213
3100564 lipoprotein complexes, 3106027 effects; captopril, percutaneous absorption,
fats; diet, orlistat, dosage schedules, 3103704 prtoacbalettesr,o l syhryudpsr,o ch3l1o0r6id2e2;7 pharmacokinetics, p3r1e0p5a5r7a9t;io nsc,l ob3et1a0s3o8l1 8;re lenaassea,l , tompoilceacl ular weight,
fefloooddi,p in3e1;0 1s4u2s2t ained-action tablets, interactions, pr3o1p0r0an7o2l9o l hydrochloride; topical, nonane effects, et3h1yl0 2a0c1e3ta te; levonorgestrel permeation, mouse
fluorouracil; transdermal prodrugs, mouse skin, proteins; oral, formulations, 3100737 skin, 3102587
3102015 protirelin; transport mechanisms, intestinal, renal eucalyptol; effects, estradiol skin penetration,
gepirone; interactions, food, 3102573 3103128
geriatrics; changes, overview, 3105817 pseepiutdhoeelpiahle drceilnles,; 3p1h0a1r6m0a7c okinetics, review, glyceryl caprylate; morphine percutaneous
glycerin; oral, pharmacokinetics, 3104641 04642 absorption, in vitro, 3105572
histidine; percutaneous, in vitro, 3104369 quinolones; interactions, drugs, food, review, gl3y1c0of3u1r2o3l ; toxicity, drug absorption, Caco-2 cells,
hydrocortisone; percutaneous, N-(2-hydroxyethyl)- 3105558; interactions, food, drugs, overview,
ib2u-ppryorfreonl;i doonienst,m en3t1s,0 31m1i5c e, 3100736; release, ra3n1it0i5d5i6n1e hydrochloride; effects, disodium Nis-eo(fpf2er-cohtpysy,dl r o3xm1yy0re3it1sht1ya5lt )e-;2 -epfyfrecrtosl,i dfoenneosp;r ofseynn thseksiins ,
cmaertbhoylxcyemleltuhlyolscee llcualpossulee,s , hy3d1r0o6x2y3p2r opyl raptey rocopnhsotsapnhtast;e ,p ar3a1m0e4t3e8r0 estimation, pabesromrepattiioonn,, i3n 10vi2t5r8o,8 ; 31m0o5r5p7h2i ne percutaneous
in3d1o0m6e2t0h1a;c int;r anpsecructuatnaenoeuosu,s , motdeerlpse,n es3, 10r1at0s1, 8 replhaxairnm;a coikntirnaecteircvisc,a l,3 1i0n6t4r6a3va ginal administration, laaubrseotrh pt9i;o nc,o lroantys, s3t1i0m3u7la8t9i ng factor, nasal
insulin; Caco-2 cells, absorption enhancers, 3104006 laurocapram; effects, sotalol transdermal
3103123; transdermal, hydrogels, iontophoresis, remoxipride; availability, suspensions, 3104382 permeation, iontophoresis, 3100193; effects,
3101424 B serine-interferon; SC dosing, pharmacokinetics, terodiline percutaneous absorption, rats,
insulin human; nasal, dosage forms, rabbits, 3106442 3106222; effects, verapamil diffusion, 3105564;
3101427 SKF-110679; nasal, availability, rats, 3103127 interfacial properties, effects, lipid-water
5-isopropyl-2'-deoxyuridine; GI, dermal, rats, SKF-L-190144; oral, ocular, animals, 3105834 systems, 3106252; morphine percutaneous
3105839; pharmacokinetics, rats, 3105840 sodium monofluorophosphate; interactions, food, absorption, in vitro, 3105572
isosorbide dinitrate; transdermal, polymeric 3104366 laurocapram derivatives; synthesis, effects,
dispersions, 3105566 ST-1435; transdermal, ovulation inhibition, 3104580
ketoprofen; percutaneous, monoterpenes, models, 3103708 (+)-limonene; interactions, ethyl alcohol,
3104680; percutaneous, rat skin, 3106210 sufentanil citrate; polyvinyl! chloride reservoirs, indomethacin, 3106201
lidocaine; alone and with epinephrine, 3100788 menthol and alcohols, ethyl; morphine
pharmacokinetics, 3100946; therapy, sulfamethazine sodium; interactions, caffeine, percutaneous absorption, in vitro, 3105572
circumcision, neonates, 3106154 3102008 N-methylpyrrolidone; ointments, ibuprofen
lidocaine, combination, prilocaine; pediatrics, sulofenur; species differences, 3102259 release, mice, 3100736
3103297 sunscreen agents; photoprotection, efficacy, monoammonium glycyrrhizinate; effects, ovine
lysine; percutaneous, in vitro, 3104369 review, 3103275 mucosa, 3106229; toxicity, ovine nasal mucosa,
mannitol; Caco-2 cells, absorption enhancers, tebufelone; pharmacokinetics, rats, 3100356 in vitro, 3103679
33110033192230; sodium caprate effects, Caco-2 cells, te3n1o0x3i9c9a6m; availability, administration routes, momnoodteelrs,p en3e1s0;4 6p8e0r cutaneous drug absorption,
mapnenrimteoalb,i lictoym,p a3ri1s0o2n1,0 4 dextrose; effects, intestinal te3r1od0i6l2i2ne2 hydrochloride; percutaneous, rats, no3n1a0n0e7; 29e ffects, propranolol topical penetration,
mmmieo3ntd1ehe0rola3tsl7r;se1 ;x6 aa tnfedo; r mduiglseatnrsei,rb iuctii nofena,qn utsie,v xatl3re1anv0ca5ys8,c2 u7lt aarbl ets, ttee33ts1r1ta0o0cs46at02ie5n2r0e3o;;n e;p ienrthceusumttiaannnael ouHesTp,i2 t9h-seoHlli vuemcn,etl lsei,fn f emvcoittdsre,o l, sm,3i c1e0,6 420 pppryopwrolierpytroyohmll xeieyaednattoelihn yokelnysg ,l;l e aynlcsecoekfol ifh neo,cfdlt ai,st c3,ta y1 ip0nsre0 tyt7rvlhia3aettrt0ruseo m;/, die3ccf1oaf0repcn3rtae1stu1,em 8;, i bau3lp1orn0oe3f 1en1a 7n d
administration, 3100419; hydrophilic molecules, tetracycline hydrochloride; interactions, calcium,
mo3irn1 p0hv4ii6tnr6oe5, 3hy1d0r4o6c6h4l;o rildaeg; tipmeer,c umteatnehooudso,l ogeyn,h ancers, thi3en1ot0peh3ry7alc8lt4ii onnes;, amvoariliacbiizliintey,, g3a1s0t2ri5c8 2;p H,s u3s1ta0i4n3e7d8-; ssooa3ddb1iis0uuo3rmm0p 3ti8cco hanop,lr aattCee;;a cotm-oe2xci chicatenyl,li ss,rm a t3 1ot0fr3 a9cahc2et0ai lo n, cildirau, g
in vitro, 3105572 action pellets, 3102586 sodium glycocholate; colony stimulating factor,
mo3r1p0h1i9n3e2 sulfate; backache therapy, creams, thienotpehryalctliionnes , anfhoyodd,r ou3s1;0 01s8u5s;t ainseuds-taacitnieodn-,a ction, naabssaolr ptaibosno,r ptCiaocno,- 2r atcse,l ls3,1 033718093;1 23t oxicity, drug
nanoparticles; phagocytosis, 3106233 3-layer tablets, 3102295 terpenes; indomethacin percutaneous absorption,
naproxen; enteric coated tablets, 3103805; theophylline sodium glycinate; transdermal 3106201; skin diffusion, mechanism of action,
percutaneous, gels, in vitro, 3106255 patches, preterm neonates, 3100208 3104390
nedocromil sodium; pulmonary, structure, crystals, thyrexine; interactions, sodium polystyrene toxicity; stratum corneum, sodium pidolate
3100592 sulfonate, 3102576 effects, 3106307
nevirapine; pharmacokinetics, dosage, 3105837 tolbutamide; dispersions, complexes, powders, urea; ketoprofen percutaneous absorption,
nicotine; transdermal patches, 3103790; 3104388 3106210; ointments, ibuprofen release, mice,
transdermal patches vs chewing gums, 3100211 tucaresol; dosage, 3105461 3100736
1070 International Pharmaceutical Abstracts
Subject Index Acquired immunodeficiency syndrome
Abuse; drugs, see Drug abuse microencapsulation; granules, 3102061 matrices; theophylline release, 3103798
Acacia; coacervates; albumin bovine, particle size, migraine; therapy, overview, 3105683 olive oil; protein films, interfaces, 3101464
stability, 3105596 otitis media; therapy, overview, 3103332 oxidation; inhibition, antidiabetic therapy,
Acacia caesia; constituents; fatty acids, lipids, overdose; acetylcysteine therapy, adverse 3103050
3100972 reactions, serum sickness, 3106051 Paederia foetida; leaves, India, 3102290
Acacia ferruginea; constituents; fatty acids, lipids, pharmacokinetics; monitoring, capillary parenteral nutrition, 3104987; total, branched-
3100972 ultrafiltration, rats, 3106465 chain, gut atrophy, rats, 3103367
Acadesine; myocardial reperfusion injury; and powders; viscoelasticity, compaction, 3101234 pentadecanoic acid glyceride; energy metabolism,
Acisacnhtehmiaam oethbeara pyk,e rarteivtiiesw , 3101556 recloeaatsien; gsm,a t3ri1x0 26ta0b6l ets, 3106028; sodium alginate Rehahimra nfnolilaic legsl,u trianbobsiat;s , is3o1l0at2i6o9n,9 identification,
npeobsoliomylguuyhtaecinxioianndms e e;st cuhlotyfmhlaeptereona upenay d,n dib ni3ggp1u,o0a l1ny9i3h1d1ee90;x 1 a9mt1eh9te rhayplye,n eo phthalmic sttaour3bxsel1itlec0aetii0astns;8ye e3;,d 1d -;ilas3 iciv tenoirtvo,ee ngr;rHd a3.on0 spt jeesla,,l p eotc3snh,1io 0cl3eeufs6mft1 ea4cstp isrs,o, p hpbyrilolacixeaisrssy , pvaamirinic,ae b,l es, AcrSeiolpraitgimhooun;xm 7p dHo,c hfnaat; emcuolnssitointuse,n tss,t abi3l1it0y0,9 7321 01447
Acantholippia seriphioides; morphology; foliar, 3101275 comparison, bezafibrate, fenofibrate, gemfibrozil;
3103438 utilization; adolescents, India, 3102958; Spain, hyperlipoproteinemia therapy, cost benefit
Accidental falls 3102541 analysis, 3101094
aalnctoihdoelpsr,e sseatnhtysl;; atbouxsieci,t y,r ev3i1e0w,0 10351 05139 Acsealtiacmylianmoipdeh,e nr atss,u lf3a1t0e;0 18m7et abolites; interactions, ph3a1r0m2a2c6o5k;i nestuisctsa;i nebdl-oaocdt iolne vetlasb,l etmse,t ab3o1l0i3t1e2s,2
Accidents Acetazolamide; concomitant therapy, 3100081 Acitretin
alcohols, ethyl; abuse, causality, 3105258; abuse, Acetophenetidin analogs; phosphonic acid absorption; percutaneous, methodology, 3104042
emmeearsgureenmceyn t,ro om3s1,0 5236110;5 30a6b;us e,a bupsree,v ention, costs, Acaelktyolpehsteenroanmeid edse;r isvyanttihveessi;s , sy3n1t0h2es7i4s8; anthelmintic Actnoxei city; side effects, review, 3106084
3re1s0e5a2r6c3h,; maebtuhseo,d olroegseya,r ch3,1 0351206523;1 3a;b usaeb,u ser,e view, Acaecttiyvli tyt,r i3bu1t0y2l7 5c4i trate beonvzeoryvli ewp,e ro3x1i0d3e;2 44t herapy, dosage forms,
a333u111t000o555m133o311b914i,;;l e,3op c1rco03ug51pr30aa05tm72is;o6, n0 a;al Sb,uw Cseaed3n,e1 an0d,S5aw 3,i1 t30z1;Ee0 ur5rl3poar1pne5edv,;,e ntU3i.1oS0n.5,, 304; ef33fe10c0Dt2s 1; f8i8ll;am usr,a mte3ec 1h0ha2yn4di0rc1oa xly laptrioopner,t iecso,m paEurdirsaognist rRaSts-, ggfillnyyaccsootlleiircci deaa;cc iiddt; h eatrnhadep rya,tp ryer,tei nvo3iie1nw0;, 3 9t53h61er0 a5p2y2,2 toxicity,
aup3tu1on0mi2os2bh6im7le en t,d ri3vi1n0g5;3 1r2e lation, ethyl alcohol, 5-m3Ae1tc0ae6bt4oy3lli7ta emsi;n oc-a6f-fefionrem, ylgaenmeitnioc- 3s-tamteuts,h yalcuertaylcaitli;on , tmeictnrroeacacymycscll,ii nnee3;;1 0t6th0he8err9aap pyy,, eeffffeeccttss,, ccyyttookkiinneess,, 33110033223311
1-(1-{4-[3-Acetylaminopropoxy ]benzoyl}-4- therapy, 3101544; musculoskeletal diseases,
Acrcecoeuinvtaiblneg,; cpohmaprumtaecry , prcoogmrmaumsn,i ty3;1 06a5c8co8u nts pOiPpCe-ri2d1y2l)6-8 3,4-dihydro-2(1H)-quinolinone, see tr3et1i0n1o5in5 7 and glycolic acid; therapy, toxicity,
Achcorspeidtiatlast; ioJnC AHO Agenda for Change, 3105272; Acetylation creams, 3106089
JCAHO standards, 3105008 caffeine; amonafide dosage, neoplasms, 3101610; Acne vulgaris
pharmacists, community; New Zealand, 3104694 metabolism, genetic status, 3106437 antibiotics; therapy, review, 3106292
pharmacists consultant; New Zealand, 3106557 Acetyl-beta-methylcholine chloride, see isotretinoin; therapy, Fordyce spots, 3106167;
residencies; ASHP program, 3105032; ASHP Methacholine chioride therapy, long term remission, 3106168; therapy,
standards, 3105031, 3105987 Acetylcysteine relapse, 3106169
Ac-Di-Sol, see Croscarmellose sodium adverse reactions; serum sickness, 3106051 keratolytic agents; therapy, review, 3106292
Acebutolol hydrochloride an3d1 0m1o3r3p0h ine sulfate; dyspnea therapy, nebulizers, ACNU, see Nimustine hydrochloride
cioncmobmipnaattiiboinl,it iehsy;d rotcahblleotr oetxhciiapziiednet;s , LDCS,C ,3 10351709032 55 N-Acetylcysteine, see Acetylcysteine Acpoolnairtougmr aphnya,g ar31u0m3;9 80al kaloids; content,
spectrometry; bulk formulations, 3102220 6-Acetylmorphine
Acediprol, see Valproate sodium ch3r1o0m2a7t8o1g raphy, liquid; urine, postmortem, Ac3o1r0u0s2 93g ramineus; effects; memory, mice,
Acaretmherittaisc;i nr heumatoid, long term therapy, 3105463 me3t1a0b6ol4i4t1e s; diacetylmorphine, neonatal skin, Ac3o1u0s3t6i1cs9; compaction; excipients, analysis,
posltryumcoturrpeh,i s3m1;0 02m2el2t ing points, solubility, N-Acetylmuramyl-alanyl-D-isoglutamine, see Acquired immunodeficiency syndrome
Acenocoumarol N-MAucreatymlyn!o rfdliopxeapctiind;e solubility; pH, 3102051 Africa; epidemiology, impact, health care,
covmepianr-girsaofnt, oacscpliursiino n alopnreo phaynlda xiwsi,t h 3d1i0p0y1r6i2d amole; Acetylsalicylic acid, see Aspirin aleccoohnoolmisym,; 3r1i0sk6,4 9k3n owledge, 3104148
comparison, phenprocoumon; toxicity, N-[2(S)-(Acetylthiomethyl)-3-(2-methylphenyl)-1- and alcohols, ethyl; high risk groups, 3104160
hemorrhage, 3103686 oxopropy!}-L-methionine ethyl ester, see SCH- antifungals; histoplasmosis therapy, overview,
spectrometry, bulk formulations, 3102220 42495 873
Acetamidocycloh synthesis, 3105759 Achromycin V, see Tetracycline hydrochloride anti-infective agents; P. carinii prophylaxis,
Acaabelsctooarhmpotiliinosonmp;; h evpnea gtetetranrsi,a nifsrme,q ue3n1c0y3 9o9f1 use, 3100177 AAcctiiocxdli ocivrtieyrd,, 8ns7ee;oe n actAoacnlyt camlmioenvnaiitnrig iotni;s , mi3c1r0o2b4i7ol1o gical, anpetfrifotepuchtbyse,lr acxumliaasnr,is f;e 3s1tt0au4tbi5eor2nc3su ,l os3is1 02t5h1e0r;ap y,P . 3ca1r0i4ni9i8 2
al3o1ne0 48a8n9d with codeine; postpartum pain therapy, AAcciiddiotsyi;s drugs; constants, LC, 3100915 antthievirraaplys,; 3d1e0v4e5l5o2p;m entth,er aprye,s eaprrcoht,o co3l1s0,3 331150; 3715
alcoonmep aarnids onw,it h keotxoypcroofdeonn,e pohsytdorpoecrhaltoirvied e;p ain mestofluotrimoinns;, lianctteirca,c ttiooxnisc,i typ,e r3it1o0n1e4a1l 3 dialysis barcetveireiawl, i3n1f0e3c3ti5o2n s; epidemiology, therapy,
therapy, 3106151 phenformin; lactic, toxicity, 3102456 ciprofloxacin; M. avium infection therapy, adverse
colorectal neoplasms; prophylaxis, lack, 3100155 solutions; peritoneal dialysis, interactions, reactions, anaphylaxis, 3103028; diarrhea,
combination, caffeine, chlorpheniramine maleate; metformin, lactic, toxicity, 3101413 therapy, 3103754
GC, dosage forms, 3103403 Acids clarithromycin; Mycobacterium avium-
comparison, ibuprofen; community sales, effects; emulsion viscosity, Z. tesmanii gums, intracellulare infection, review, 3100816
3106494; sore throat pain models, pediatrics, 3100786 clarithromycin, ethambutol and rifabutin; therapy,
3101625; toxicity, pediatrics, 3101889 neutralization; calcium carbonate, toxicity, 3105118
compression; direct, solvation, desolvation, thermodynamics, 3103839 clindamycin; pharmacokinetics, 3102817
3106024 Acids, fatty cytarabine; leukoencephalopathy therapy, 3100678
concomitant therapy, 3101867, 3102470, 3103674 Acacia caesia; constituents, 3100972 didanosine; HIV infections therapy, 3105626;
consumers; consumption, community pharmacy, Acacia ferruginea; constituents, 3100972 therapy, HIV, resistance, 3104648
survey, 3104146 binding; proteins, estimation, methodology, drug abuse; IV injections, needle exchange
dissolution rates; tablets, formulations, 3103150 3106457 programs, 3103476; IV injections, risks, survey,
dosage forms; liquid, tablets, pharmacokinetics, butyric acid derivatives; pharmacokinetics, 1984-1992, New York, 3103472; prisons,
availability, 3100735 toxicity, rabbits, 3106415 3105286
dysmenorrhea; over-the-counter, 3104515 chromatography; food by-products, 3101810 drugs; metabolism patterns, 3101600
enterocolitis; pseudomembranous, therapy, survey, Dalbergia sissoo; constituents, 3100972 education, pharmaceutical; and HIV infections
3100705 effects; body odors, 3101484; ketoprofen awareness program, students, 3103524; students
extrusions; pellet properties, hydroxypropyl percutaneous absorption, 3106210 knowledge, attitudes, 3103496
cellulose effects, 3102400 evening primrose oil; atopic dermatitis therapy, epidemiology; and tuberculosis worldwide, WHO,
granulations; surface active agents, 3100596 3101978 3106545; investigational drug therapies, 3105663
headache; therapy, 3102101 fatigue syndrome; chronic, review, 3101502 erythromycin and tetracycline; bacillary
interactions; isoniazid, excretion, 3106194; gamolenic acid; rheumatoid arthritis therapy, angiomatosis therapy, 3103058
salicylamide, metabolism, rats, 3100187 toxicity, 3106158 ethambutol, clarithromycin and rifabutin; therapy,
mechanism of action; efficacy, review, 3102694 Gymnosporia montana; leaves, India, 3102290 toxicity, 3105118
International Pharmaceutical Abstracts
Acquired immunodeficiency syndrome Subject Index
fluconazole, comparison, ketoconazole; oral herpes zoster; therapy, toxicity, anaphylaxis, octreotide acetate; TSH-secreting pituitary,
candidiasis therapy, cost benefit analysis, 3101384 therapy, 3101945
3101092 herpesvirus infections; therapy, mice, models, Adenomatous polyposis coli
foscarnet; cytomegalovirus retinitis therapy, 3102299 sulindac; familial, rectal, therapy, 3101333;
3105483 incompatibilities; IV injections, infusion pumps, therapy, 3106126
guidelines; pharmaceutical industry, WHO, 3104981 Adenophora species; polysaccharides; isolation,
3105303 resistance; herpes simplex, 3103718 identification, spectrometry, 3100393
immunization; vaccines, clinical studies, ethics, teratogenicity; lack, 3102457 Adenosine
developing countries, 3104114 varicella-zoste~: multifocal cerebral lesions, adverse reactions; accelerated atrioventricular
ketoconazole, comparison, fluconazole; oral 3102553 conduction, 3103648
c3a1n0d1i0d9ia2s is therapy, cost benefit analysis, Acryepcolrotvs,i r teirna tPogreenginciatnyc, y laRcek,g is3t1r0y2;4 5a7c yclovir; co3r1o0n1a5r6y0 ;d isteesatsse,; rdeivaigenwo, si3s,1 03s8c5in8t igraphy,
mortality; vs lymphoma patients, 3106310 Acyclovir sodium dosage; activation, renin-angiotensin system,
paromomycin; cryptosporidiosis therapy, 3103727 herpesvirus infections; therapy, mice, models, hypertension, 3101559
patient education; role, community pharmacists, 3102299 dosage schedules; side effects, myocardial
3102368 stability; injections, 3104976 imaging, 3102495
pa3t1ie0n4t1 86in;f orcmoantsuilotna;t iocno,n suplthaatrimoan,c y phsatrumdaecntiss,t s, Adagen, see Pegademase bovine inmteermabcrtiaonnes,; tkriadnnsepyo,r t 31s0ys1t5e3m9, brush border
sociology, 3101739; pharmacists role, 3101144 Adalat CC, see Nifedipine mechanism of action; bronchoconstriction, rats,
rifabutin; Mycobacterium avium-intracellulare Adalat Retard, see Nifedipine models, 3101574
trseiudcitpsfltrionrafsyxafoba;iserug dctcrtriiathiseatlienksyzlo,ai,siun ,n irn,, ioec 3a;nlC,1d p,.a e0r rlto5id3a3po1ti1hyx1f1h0fyeo0r8i3ldpo2c a6 lim0xl7ay9tie0sc5,ysmi p ,one 3 s 1i3has01yn 60pd0e0 tr56hse98eet 9rnha;sap imyt,bti uovxtitiotoclyxi,i;tc yi,t tyh,e rapy, AAdddosddprostiiicuryaccigerttto aieisltnsaoo mg;bgne euy,n s;l te ee ;xsv iepcoemrhmI pVoaea,gDtnc rehgtSaae,pcm d eosytnf,p!lad r ameoni3gnmdl1ri,ace0a iesm5n ,3s9t 1,0e 0n334a 131n015c407e1;6,5 533 nn5ea erdcloet,i c AAddcttueeoethrxrienneileroovicbasizsirpateiaiytywln;ni;, eoe n im;m3s yedr1coceeh0hchuca1easaemm5rpnpii6ditiatn7ios aa arlm!sps s e,r,a o igpsUohiacKnynshi,lhetsai mhtxbimssiiaau st,,r,o v resryrg;he,e i prnebpi3irtelf1inssu0t,,so1 is6ot339an117t 00i 11ni5;n5j 78u50r y ,
teatnrgaicyocmlaitnoes iasn d theerryaptyh,r om3y1c0i3n0;5 8 bacillary Adcdriysttiavlelsi zation; surfactant effects, review, 3105602 deroatxsy, ad3e1n0o3s3i5n0e derivatives; seizure prophylaxis,
dilazep; seizure prophylaxis, rats, 3103350
therapy; isopolyanions, heteropolyanions, injections; acyclovir, stability, 3104976;
3103365; survival, 3105474; tuberculosis, aminoglycosides, incompatibilities, dextrose, pentostatin; seizure prophylaxis, rats, 3103350
3102183 stability, storage, 3103844; ampicillin stability, Adenosine triphosphate; neoplasms; antitumor
women; demographics, therapy, U.S., 3106517; buffers, 3102643; anakinra, incompatibilities, effects, overview, 3101566
developing countries, increased incidence, ceftriaxone, 3104972; anakinra, incompatibilities, Adenosine 5'-triphosphate, see Adenosine
3100480 cimetidine, famotidine, 3104973; anakinra, triphosphate
zalcitabine; HIV infections therapy, 3105626; incompatibilities, lorazepam, 3104974; Adhesion
therapy, toxicity, costs, overview, 3103340 aztreonam, incompatibilities, ampicillin- biological, see Bioadhesion
zidovudine; antibodies, prediction of prognosis, sulbactam, 3105194; bupivacaine, carbomer 934P and glycoproteins; effects,
3102163; prophylaxis, cost benefit analysis, incompatibilities, polypropylene syringes, theology. 3104419
3103480; prophylaxis, HIV infections, 3101345; stability, 3100242; caffeine, incompatibilities, catheters; vein wall, toxicity, neonates, 3103675
resistance, blood, CSF isolates, mutations, glass, 3104443; cefazoiin-metronidazole, cosmetics; effects, nylon microspheres, 3104398
3101615; therapy, 3104568; therapy failure, incompatibilities, 3100251; ceftriaxone, diazepam; excipients, models, 3101006
alternatives, 3105626; therapy, HIV, resistance, incompatibilities, aminophylline or theophylline, glycoproteins and carbomer 934P; effects,
3104648; therapy, long term, 3105616; therapy, 3102639; ceftriaxone stability, 3100790; rheology, 3104419
mortality effects, 3105475 cefuroxime, incompatibilities, aminophylline, labels; glass containers, energy vs acid-base,
Acquired immunodeficiency syndrome vaccines theophylline, 3105196; ciprofloxacin, 3104242
imcmouunntirziaetsi, on3;1 0c4l1i1ni4c al studies, ethics, developing i3n1c0o3m8p4a7ti;b ildiatliteesp,a ripne riitnocnoemapla tidbiialliytsiiess ,s ol3u1t0i2c0as7,3 ; su3cr1a0l3f8at3e8; bioadhesive GI retention system,
immunogenicity; dosage, 3101899 d3i1p0e3p3t5i5de;s , fapt areemnutlesriaoln sn-uptarrietniotne,r alr evineuwt,r iti3o1n0 3343, Adhesives
Acromegaly incompatibilities, 3100794; fentanyl, biological, see Bioadhesives
bromocriptine; therapy, 3102655 incompatibilities, stability, 3105198; fluorouracil, labels; glass containers, lubricants, effects,
octreotide; therapy, 3102655 incompatibilities, leucovorin, stability, 3100792; 3104242
therapy, 3104487; dopamine agonists, foscarnet, incompatibilities, stability, 3102063; Adinazolam; comparison, lorazepam; toxicity,
somatostatin analogs, 3101561 ganciclovir, incompatibilities, parenteral behavioral effects, 3105440
Act-HIB, see Haemophilus b polysaccharide nutrition, 3103849; haloperidol, Adinazolam mesylate
conjugate vaccines incompatibilities, vehicles, stability, 3105195; absorption; rats, dogs, 3106208
ifosfamide-mesna stability, 3105526; release; polymer matrices, methodology, 3105588
Acctoimdboisnea tiwoint,h sSoorrbbiittool l, see Charcoal activated; iinnfciolmtpraattiiobni licthiaersa,c tesrtiasbtiilcisty,, 33110054492891;; iinnttrraavveennoouuss , AAddjmuivnainsttsr,a tisoene Excipients
AAccttiilnyesxe,, sseeee MAaltseopplraosceo l pienpctoimdpeast,i bidliistciuesss,i onc,o nt3a1in0e3r3s4,7 ;s talboilriatzye, pa3m1,0 3851; AmCeerntiecra n foAr sstohec iaAtdivoann coefm eCnotll egoefs Phoafr mPahcaerumtaiccya;l
Acitdiennitidfiiac atkioonl,o mi3c1t0a0;4 01c onstituents; isolation, immneocdloismcipaadttoiimobinin leite rireposhr,so ,t ostdlaaebbcielolimitpyn,go ,s i3t13i01o10n41,72 24;53 ;1 04m4e5l0ph;a lan, AmEedruciactaino n,S oc3i1e0t5y3 2o1f Hospital Pharmacists;
AAccttirvaapsied,, sseeee AIlntseupllians en eutral eanfniftteirc-otigsnl,fy ecc3etr1ii0vn0e,7 0a7sgt;ea bnitlosin,td ya,3 n1sc0eot3nr8to4ani3,n;e rsip,na ccolcmiltpiaanxtieiclba,li lities, CeErnedtsueicrda etnifcooinre ;s ,th eA mAaACtdPcv,ha innc3ge1 m0p5er3no2tg7 r aomfs ,P ha3r1m0a0c4e9u8t ical
Actrapid HM, see Insulin human incompatibilities, infusion pump sets, 3101469; clinical pharmacists; professional competence, job
Actrapid human, see Insulin human p3a1c0l5i2ta0x0e;l , ppacolliytoalxeefli,n sctaobnitlaiitny,e rs3,1 0s4t9a7bi8l;i ty, cldiensiccarli ptsitound,i es3;1 information technology,
Acaydcvleorvsei r reactions; IV therapy, vesicular eruptions, ppaarreenntteerraall nnuuttrriittiioonn, isntcaobmilpiattyi,b il3i1t0i4e9s7,9 ,3 130140954053;8 ; pphhyasrimcaicaenust icraolle , ientdhuisctsr,y , 3130130417788 3; multicenter,
3103649 quality assurance, hospital pharmacy, 3104867; computers; programs, validation, 3101173,
alone and with prednisolone; dosage schedules, ranitidine, incompatibilities, stability, 3103850; 3101196; programs validation, total quality
chhiecrkpeensp ozxo;s tero,r al3 1t0h5er4a8p8y , overview, 3106304; r3a1n0i4ti9d7i5n;e , rienacdoym-ptaot-iubsiel itIiVe s,s ysvtiaelmss,, syorvienrgveise,w , minadnuastgreym,e n3t1,0 1137160 1194; validation, health care
prophylaxis, pediatrics, 3101355; therapy, 3101209; safflower oil-soybean oil Connecticut Society of Hospital Pharmacists;
economics, 3100486 incompatibilities, 3106286; satellite hospital pharmaceutical care activities, 3104856
comparison, 5-isopropyl-2'-deoxyuridine; clinical pharmacy, 3104879; sufentanil-bupivacaine contracts; hospitals, industry survey, 3106532
cosmtpudaireiss, ono,v ertvrioemwa,n ta3d1i0n5e4 64h ydrochloride; topical, ivnicnoomrpealtbiibnieli-tcieepsh,a lopsoployrviinny l inccholmopraitdieb,i li3t1i0e0s7, 88; Deppraocretsmseinntg , oAfu sHteraalltiha;, n3e1w0 23d2r2u g applications,
herpetic stomatitis therapy, 3100655 3103852 drugs, see Drug administration
cytomegalic inclusion disease; ]V prophylaxis, education, pharmaceutical; clerkships, 3105339;
renal transplantation, 3101966 Adoevenrivniee w,n uc3l1e0o1t5id6e6s ; effects; tumor cells, curriculum, 3101762; curriculum, perceived
encephalopathy; therapy, hepatitis A vaccine needs, students, graduates, 3103540; sociology,
toxicity, 3100102 Adenine 1-N-oxide, see 1H-Purin-6-amine 1- 3101763; strategic planning, 3101758
glossitis; therapy, herpesvirus infections, 3103717 oxide Food and Drug Administration; approvals, quality
herpes simplex; effects, organ transplant patients, Adenoma of life, methodology, 3102888; management,
3100378; therapy, 3103949; therapy, models, aspirin; !arge bowel, prophylaxis, surveys, internal operations, 3101058; streamlined
methodology, 3106450 3101374 approval process, 3106479; user fees, 3106480
1072 International Pharmaceutical Abstracts
Subject Index Administration
health benefit programs; prescription drug 3100041; pharmacists, technicians, career Occupational Safety and Health Administration;
coverage, 3105944 development, 3101833; — technicians, overview, 3105007
health care; businesses, cost control, 3101075; training programs, 3101836 personnel; age factor, guidelines, 3101662;
costs, state spending estimates, 3106546; effects, pharmacoeconomics, 31050 10, 3105018, management, guidelines, 3105295; management,
hospital pharmacy practice, U.S., 3101660; 3105026, 3105051, 3105300; human behavior, communication, 3101072;
pharmacists role, developing countries, 3101704; pharmacoeconomics, critical path analysis, pharmaceutical industry, Taiwan, 3104762
reports, antitubercular resistance, 3105206; 3105030; pharmacoeconomics, DRGs, 3105027; personnel, pharmacy; termination, guidelines,
students, interdisciplinary team, rural pharmacoeconomics, roentgenographic agents, 3106475
communities, 3101759 3105025; pharmacoeconomics, thrombophlebitis pharmaceutical care; ambulatory clinics, 3104267;
health maintenance organizations; quality prophylaxis, 3105024; PHS indigent patient pharmacy services, ambulatory care, 3104910;
assurance, patient consultation, 3104934 programs, 3105294; productivity, parameters, strategies, 3102349
home health care; IV infusion, physicians 3100056; prothrombin time test utilization, pharmacists; asthma ambulatory care clinic,
attitudes, 3105037 3104862; quality assurance, 3104916; quality effectiveness, 3100514
hospital pharmacy; adverse reactions reporting assurance, air quality control, 3104835; quality pharmacists, community; job description,
programs, 3105052, 3105063; allergies, assurance, automated dispensing, 3104846; 3102373, 3104799
dwoarcfuamreinnt attiheorna,p y,3 130140943815;8 ;a mabnutliabitootriyc s cafroer,m ulary, qquuaalliittyy aassssuurraannccee,, omveedrivciaetwi,o n 31er0r5o1r0s,6 ; 31q0u4a8li8t5y; ph3a1r0m3ac4i8s4t s, hospital; biotechnology products,
3104941; anticancer chemotherapy, 3104906; assurance, pharmacokinetics monitoring, pharmacy; audits, 3101774; computer programs,
aeaataa3rpa3ugicnqeu1uh1demctstuta00ineriioior14tt ecdmmpms88sdoea,ama3,4sian ttcet 23tgciuiin;;qeuydo3ostud l inn1ta, ea,,0ls aasan i4 r,cuutt ev9ctt ys3bsar0oo e3li1oe7cmmlid1n0dl;aeaadeiu0i4s canttnst48stticeeae8i3uaciiddtso,r58noei ,n ant1,so, n,i,; n3 dp cn 13ieee33se013,3oa1s1rp5 01p1nt0 0el0400ta4n4Ga124i5rns8rs82n68ed0ie4t4ev;a443nai5o4ir ;92gct,ped; ;;,s lw sa a,,ncBs 3tbhr3dAAtei1iia1i33SnnS0tsnc01e1eat4HHgs4f0io0r8,eiP8nPpi554 t,,3bl 00 s7 ua643,;ts, 91i t ;;oin c, c3333rr3333g3leee111111111issr000000000niit442144i443adrc884899t996euar57233n3c932litt270403058 csu,;;;;;;;;s rs , it wnuqr3rrssssgdodaueeeee1e,irrtacsrrrg0 eekulvivrvis4lii igdiuo,l38tcceci i n16yeeentlta0rs s7esco3mle,,4,,ai;e1ia l de8 n0zas,s5tset3dees ,tq,7edidu6x eu cd;a urpr4ao biacAa2slpplenanti;pShetrhct st r aeHeioayiors,boep Prosbm e nrnanm lan,itot,aemcees mdg fesilmtcpuielltesshyctirl3rnate, t,ition1osa el tsd0vgl,,eus a t r3e3 3serha0m1,1rspmd tp vt1e00rsaeaih84n0co,nbcgcia;9 dt0ieheprcul 56,rsneoi 3ci01, i,twats1 c ;;ytaese0i, rrg,Jr a5ive an,9cinpss8 cta,,e7sn s,;,, cjsafuciDiiHaogylnpnomeUresbovvgpameEntwee ralp,c nenac t daitmtdthenceo3so,e srhirs,r1 ,ceaey, yS0r srs, 3 eie4t ,313pra9i3c 1trv01nd31oici050gi2n0ohic,191at;,n3ne 1b11r ,d 5e7o07 u35tl1;c2sri16e,o;s ;ine0 s;lu rf f 4 lrpyloc8vad uhcrome2bfeemaoemyoo2icnsrmlp,rrmic;,mlpu ampse iauttuai tct3eilcoc3uie1orattns1osrn0ars , 0mct,si5, t2p se,ap 3i9us 3n r0c5sa,t1so38tjl,6 pde01a;o y;out6r0 sbpeic 5 32i,a nt5 s1m9ttsOss,6i08 a,afy eB;68 tneosn 5i;Rd3aftt3se8 1geAfNr130smaeaaf0 ;ac4 ltmo5l t7 icee3i18o uo5n9n6sn6t9a;,e;0l d
management, 3101256; clerkships, models, costs, sexual harassment, cases, 3104083; staff 3106582; pharmacoeconomics, methodology,
3104174; clinical pharmacists interviews, development, pharmaceutical care, 3104936; 3105000; practice, image development, 3105348;
3104875; clinical pharmacists, job performance, staff pharmacists job satisfaction, Australia, prescription drug repackaging, costs, 3102344;
3103027; clinical pharmacy traineeships, 3101830; sterile products, quality assurance, procedures, inspections, South Africa, 3104100;
3105028; clinical services, 3105003; clinical 3104841; technicians careers, 3104261; purchasing, guidelines, 3103567; relief work,
services, ambulatory care, 3104872; clinical technicians newsletters, 3105070; therapeutic 3104192; transition, pharmaceutical care,
services, ambulatory care, polypharmacy, substitution programs, 3104944; training 3101147; trend analysis, 3101668
3104874; clinical services, cardiopulmonary program, 3104864; trends, opportunities, threats, pharmacy, community; accounts receivable,
resuscitation team, 3104922; clinical services, 3102428; unit-dose dispensing, quality control, computer programs, 3106588; business
expansion, 3104882; clinical services, ICU, 3100062; unit-dose packaging phaseout, improvement, 3106537; chain stores, careers,
3104896; clinical services, skilled nursing 3105298 3106578; customer services, 3101127; financia!
fpahcairlimtaicesi,s ts3 10r4o9le2,4 ;V A,c lo3z1a0p5i0ne8 8;t hecroampym,u nication, hopsrpoitgarlasm;s ,a dv3e1r0s4e1 98d;r uga mrienaocgtlioync osriedpeosrt,i ngc ost m31a0n1a0g8e4m;e nti,n for3m1a0t5i9o9n4,; cgoemnpeurtaelr s,m er3c1h0a1n1d6i2s:e ,
3100609, 3101243; computers, 3100554; minimization, 3101108; antibiotic cost control, niche marketing, 3101675; patient consultation,
computers, information systems, pharmacists 3100610; antineoplastic agents, environmental pharmaceutical education, 3105337; personnel
role, 3101782; computers, LAN based Windows, toxicity, Germany, 3104082; biotechnology screening, 3106567; pharmaceutical care
3105066; computers, pharmaceutical care drugs, committees, 3100613; cost benefit services, marketing, 3101126; planning and
documentation, 3105075; cost benefits, antibiotic analysis, antibiotics, therapy, 3105013; drug design, 3101135; point of sale computers,
therapy, 3105290; Denmark, 3102425; diabetes utilization evaluation program, 3105095; needle 3104210; profits, 3101674; profits, reports,
mellitus, ambulatory care, 3104899; downsizing, selection, safety, 3105391; OSHA regulations, computers, 3101786; purchasing, negotiating
factors, 3105100; drug costs, 1994 projections, 3105005; team, drug cost control, 3101068 guidelines, 3106495; services, success, 3104182;
3103474; drug costs, consumers attitudes, industry; quality circles, 3105964; quality small business status, survey, 3102381; staffing,
3105020; drug costs, health care reform, management, 3104756 3101133; theft, prevention, survival, 3101776
3105022; drug distribution systems, expiration industry, pharmaceutical; centralized drug Pharmacy Guild of Australia; issues, 3106559
dates, 3104917; drug diversion monitoring, OR, distribution, 3104709; computer validation, pharmacy, institutional; drug costs, 3105029; long
d3r1u0g0 32i5n;f ordmrautigo ni nfsoerrmvaitceiso,n , eveadluucaattiioonn,, 33110055006303;; 33110011119925;; ccoonmspturtuecrtsi,o n dopcroujmeecnt t mamnaangaegmeemnetn,t , t3e1r0m3 6c3a9r e, continuous quality improvement,
drug inventory, legal responsibilities, pharmacist, 3104711; define business, 3106498; drug recalls, pharmacy services; anticoagulant monitoring,
3100463; drug utilization, 3104901; DUE 3102959; Good Manufacturing Practices, 3104850; anticoagulants, 3104868; antimicrobial
programs, clerkships, 3101115; DUE, protocols, training programs, 3101202; health care reform, susceptibility cascade reporting system,
3104865; enoxaparin, formulary management, effects, 3104120; impact, health care reform, 3105056; clinical, postpartum therapy, 3104889;
3104886; formularies, drug information centers, 3106520; Indonesia vs Western Europe, consultants, patient focused care, 3104918; drug
3105054; formularies, manuals, 3105055;
ipihhJ3cmnnhoao1eCtvnazd0mAeesrai5egsumrHc0 rtlada6Oaitcot4tgahi uieae;nssdotat ts linsstto, I,ahpns V nraue adlerbctca frasaetrofdtrcidrdimeahcsscr,inn e,i unci egiectIn ssmie3cVta oays1 rnmde 0as,seir5t, anlve0 ifjixsee93ocp,ct3ne7e1 tysr 1;0i ,t0 43o ss1p18n,ym8src06 s,3ooa41t 35gm8;ner;1p8 3pma 0u01somt0m;,0wi,e0 4le r48irs30i8t3,n1 ;a71t 0 r;e04y r4 8v85ia79en0;wd;s , lecp33r3mm3ahr111eea1dao000ca0nelb451ors1all720sm0ugeeh697m2rnemi9185geemsp;;;e;nm;e,s de n,ant ppsphtctar,eeho,ilo3ra aref o1lsrrsint0o,e3tm3hs n1c 1a 1,nt1c0cp0ie 0cuer4o2lt2aue1ns 9r3;sts4,e61 ci, t 350r cr ;rii4aaro bm3i2ellepn1f5 eitrao,03on-c r4c;tgltmaa2 ,hi,r,l e1ne ar9,keleq 3;Aevtus1d Sahae3 0l Cla1q6uiPr0upca5tc,a1aet4yhlr 7ir 9 eio6f; tn17ob y,9;arr 9s emp3cefra,odoon n,jrct emrec,ot ls,, dea3rt3cmnvedhoou11aaletmno00nrlirsim44iauavuss99tpaelgs,i24ytrtie o3,2iyaond o; t;3,n ni s13i,o,01c nmhhI a40,opoVr83 4ssr e3p918p o1i3i1i08v0tn1cs;43eaj4e0y8 ;lem9ss48 c e,4t8i1t n9eam7ii;mt;toen3 3snr, tr,1s,org e 0, gaeip t4ern3i3hn39std1n1ei13e,ue0c0cr07 roa4 4v4a;nl89e3l9 a r7n3 1t0e6t4del05hi;a;asro4;on t ,su9 nea pg4sddlip ,p6 grta3 a;eiaut1rh nlsig0eoIf ei snV4unpapt e9stua ie itmt6ttroiipeo8aalne r;rlli,no o g z trgae artnlia comny,
c3333i1111v0000i143l0i0960a6035n9239, ;;;; 31mmnN0uueH4llwStt2 ii 6cc6Iuur;Clle tUtfuu omrrraiapmllso, ss iitppnGieegrorr enssa,odot non nsnmeeeBal lrr,,ikh t eoattibwlineoi,nnrn egekf,,3si t1hs0o,1p 6,8 4; lepsggcuhihiasodlroeamlltasiico,nin es;s t3,s 1r 0e31gm17ue06ln14at7t,oo5 rr2sy3 , 1 0p35r13oc00e69s5,s8 ,0 3;13 015p03h11a09r2;m6 a csyc hools, ceefoddonuucsccuuaaslttetiidaoo tnni,,co anr,evv, ii ddpee3ioo1ctt0taa4opp9geer4ssa8,,m ;s 3,H 1pM0aO3t5si10e,04n5 8t0; 53 i91n;p0fa 5ot0rip7mea2anttt;i ie ontnp ,a tient
paroxetine DUE criteria, 3105147; patient care, managed care systems; drug costs, 3105021; anticonvulsant tables, 3105069; patient
333111000044098325655,,, 333111000045090304893;,; 3ppaa1tt0ii4ee9nn1tt 2,fo ouct3uc1so0em4de9 s1,c3 a,r e3,1 30140941911;4 , gspeehrnaverirmciaeccs ,i sdtr3su1 g0 4rpo8lo6el0,i ,c i3e1s3,01 40943091820 94;1 63p;h aprhmaarcmya csye rvices, ci3an1rf0eo4,r 9m1a39t1;i0 o5n0p,4h 2a;pr emdaipcahitasrrtimcsas ,c erou3lte1i,0 c5a30l16 074;c8 ar9ep3 h;a orumptracecosemcuertsii,bc ianlg
performance measures, Sweden vs UK, management; careers, men vs women, 3104776 error prevention, 3104920; prescriptions,
3100058; personnel cooperation, 3104915; manufacturers; alcohol abuse programs, 3104164 terminal care, 3104940; primary care,
pharmaceutical care, 3104894, 3104927, meetings; planning, 3102933 pharmacists role, 3104921; professional
3105040, 3105047; pharmaceutical care, health National Association of Retail Druggists; 1992 relations, nursing, 3104871; staff development,
care reform, 3105017; pharmaceutical care Annual Report, 3104194 3104878; technicians order entry, 3104943
implementation, 3101258, 3104892, 3105400; National Health Service; physicians prescribing, policies and procedures; audits, pharmacy, third
pharmaceutical care, recruitment, 3101837; costs, generic drugs, reforms, 3101656 party contracts, 3104695; automatic stop orders,
pharmaceutical care training program, 3104869; nursing; IV therapy, project management, hospital pharmacy, 3104854; decubitus ulcers,
pharmacists, retirement, emotional preparation, 3105931 consultant pharmacists role, 3103637; drug
International Pharmaceutical Abstracts
Administration Subject Index
information centers, Montana, 3100548; ethyl smoking; cigarettes, prevention programs, meta- pharmacy, community; analysis, 3104758
alcohol, LTCFs, 3100047; home IV therapy, analysis, 3101687 pharmacy services; consumers, 3104128
3103600; hospital pharmacy, manuals, Adrenal gland hypofunction; dexamethasone; regulations; pricing, prescriptions, South Africa,
computers, Spain, 3106016; hospital pharmacy, therapy, high altitudes, 3100165 3104099
nonformulary prescribing, physicians, 3101242; Adrenaline, see Epinephrine Advisory Committee on Immunization Practices,
hatotsiptiutdaels , ph3a10r1m2a4c4y; sneruvrisciensg, hToPmNe,s , phmyesdiicciaatniso ns AAddrreenneerrggiicc abgleonctksi,n gs eea geSnytsm,p astehe omSiymmepattihco lyatgienct s sAedev iUsnoirtye dC oSmtmaittets eeP ubolni c ImHmeuanlitzha tSieornv icPer;a ctices
wfarsotme hdoimsep,o sal3,1 00h6os1p2i;t alosp, ht3h1a0l3m6i3c2 ; proeppiaartaetsi ons, agents AeroBid, see Flunisolide
diversion, home infusion services, 3105275; Adrenocortical steroids, see Steroids, cortico- Aerosol OT, see Docusate sodium
OSHA inspections, 3105006; parenteral nutrition Adrenocorticotropin, see Corticotropin Aerosols
compounding, automation, 3104839; patient Adrenoleukodystrophy abuse; adolescents, _— detection,
discharge medications, England, 3105104; erucic acid, combination, oleic acid; therapy, management, 3100497
pharmaceutical industry, environmental lymphopenia toxicity, 3105117; therapy, albuterol; cardiotoxicity, pediatrics, 3106080;
protection, 3101632; pharmacy schools, hepatitis overview, 3100123 inhaler-spacers vs nebulizers, pediatrics,
sBu rvvaeciclilnaensc,e, 3n1o0m5e1n8c1l;a tuproes,t ma3r1k0e2t3i5n9g; therapeutic Adrenolytic agents, see Sympatholytic agents b3r1o0n5c5h2o4c;o nsttorliecrtaincoen,, a3l1le0r1g4e9n9 induced
substitution, hospital pharmacy, 3103023; Adrenomyeloneuropathy albuterol sulfate; compounding, inhalers,
tuberculosis therapy, HIV infections, review, erucic acid, combination, oleic acid; therapy, 3100765; dosage, asthma, pediatrics, 3101970
3101702; validation procedures, computers, f3a1i0lu0r1e2, 3 3100124; therapy, failure, overview, amphotericin B; prophylaxis, pulmonary
industry, 3101185; wholesalers, consultant aspergillosis, 3101968
pPhDaMrAma cym ansuearlv,i ces3,1 013116032 972; wholesalers, Adserei aDmoyxcoirnu bicin aannatliypseirss;p iraaunttosm; atdieovne,l oapcmteunatt,or rseygsutleamtsio,n s,3 104255
product development; quality assurance, efficacy, see Doxorubicin hydrochloride packaging, 3100470
toxicity, 3103618 Adsorbents asthma; metered dose inhalers, content estimation,
research; writing proposals, 3104201 aluminum hydroxide oxide; phosphates, in vitro, 3100007; pediatrics, 3102156; therapy, review,
schools; pharmacy, deans, 3101765 3102024 3102125
strategic planning; guidelines, 3101125 aluminum oxide; adsorption, oleic acid, sorbitan azelastine, comparison, budesonide; allergic
Wal-Mart; business practices, 3104801 trioleate, 3102041 rhinitis therapy, 3100704
wholesalers; computers, 3101154; computers, charcoal activated; bromocriptine toxicity, beclomethasone; long term, toxicity, cataract,
truck routing and scheduling, 3101153; disaster 3105422; chloroquine poisoning, 3100627; 3102452; toxicity, cataract, lack pediatrics,
planning, 3101721; financial management, combination, sorbitol, phenytoin toxicity, 3101848
3101685; inventory control, 3101681; 3106129; FDA regulations, 3101639; isradipine budesonide; asthma, pituitary-adrenal function,
pharmaceutical industry, future, 3106531 poisoning, pediatrics, 3100640; lamotrigine pediatrics, 3101844; relation, blood, tissue
Administration sets, see Surgical supplies; poisoning, 3104297; morphine toxicity, 3105818; levels, lung neoplasms, 3103428; toxicity,
Adacmldiimnininiciaslst trrpaahttaiorormnsa cissettss ; professional competence, job Addsipaoorrirpshteoain;oi nng t hetrhaeprya,p y,3 10pe4d5i3a5tr ics, review, 3103271 bucrdahietnasirotanicsit d, et,hl earccakop ym,ppe adr3iia1st0ro0in7c,s0 ,4 az3e1l0a1st8i4n8e ; allergic
aluminum hydroxide oxide; albumin bovine, in cromolyn sodium; structure, crystals, 3100592
description, vitro, 3102024 cyclosporine; liposomes, lung deposition, 3102609
gu3i1d0e1li6n6e2s;; ppeerrssoonnnneell, maagnea gfeamcteonr,t , gui3d1e0l5i2ne9s5, caemtirniom oanciiudsm; barlaonmiindee ; craysntda lss,u rf3a1ct0a4n4t1s5, durapatite, de3o1d0o0ra4n7t0s ; development, regulations, packaging,
hop3sh1pai0rt1ma2la4 c3ip;sh tascr,om masmcuuyrn;vi ecya,at ttii3to1un0d,e5s 0,9 s0tb;aef nfe cfpoihtmasm,ru mnaiwccoiasmttesin,o n, dr3u1g0s;3 82e7nt eral nutrition tubing, review, 3100714 a3 10015 ama cystic fibrosis therapy,
nitroglycerin; IV tubing, clinical effects, 3103719 flonisolide: metered dose inhalers, dosage
3100609; economic outlook, 1993-1994, octoxynol; and surfactants, durapatite, 3193827 delivery, 3100561
3105296; manpower, schedule changes, vacation
oleic acid; albuterol, aluminum, isoproterenol hair sprays; =o gas compressed
l3e1a0v5e9, 873;1 02t4i1m8e ; alrleosciadteinocni esm,o deAlSsH, P 31s0t4an9d9a9r ds, somdiicruomp arltaiurcylle!s ,s ul3fa1t0e2;0 4a1n d surfactants, durapatite, Ris ysteemes, 3f1e0 07S4(t oxime; lun
hoisdpeinttailfsi;c atrioolne,, d3r1u0g1 8a2b7u se, prescriptions, 3103827 deposition, vapor pressure, 3103119
pPshec1cah9kor9o,m2l a,scC ;i. s;3t p1sh0F;a1D r6Am9s,aa9 lc ayri,ine tse,dr evaijneoswb,s ,s a3t13i01s10fa70c64t54i o2n , Mississippi, sstouam3rfmi1beocin0xrtt1ioaa4fpnnea7i nrl6;t;t ri icoelclpeoeisnad,ttu aer;ia n3le1a r0lsb2a,u0d tm4eic1ren olills, t cruialsttoiuporrneo, t esr3ye1snt0oe4lm4 s4,4 inmneoa3hbdda1uemll0liei0snrz5;sie; s6r t7srl ;dau etnvigiio ncnhed,ase l,pa otpsiraioostntt,ieh iomnnpsa a, r ptatisthtctealerberai nlpsiys,ti,y z ,e 3 3113e00v14a500l30u471a789t ;4i o nd,r ug
Admixtures, see Additives; injections tamoxifen derivatives; containers, cell culture, nedocromil sodium; structure, crystals, 3100592
Adnexitis 3104444 nicotine; smoking cessation, 3106348
sulfamethoxazole, combination, trimethoprim; Adulteration; ginseng; overview, 3104529 nitroglycerin; sublingual, cholelithiasis, pain
therapy, toxicity, leukopenia, thrombocytopenia, Adverse Drug Reactions, 3103648 therapy, 3102519
3102467 see also 3100182, 3101011, 3101180, 3101189, pentamidine; P. carinii pneumonia prophylaxis,
therapy; overview, 3103157; review, 3105645 3101240, 3101384, 3101399, 3101400, 3101417, 3105474; P. carinii prophylaxis, 3104523
Adolescents 3101498, 3101600, 3101779, 3101785, 3101787, pentamidine isethionate; nebulizers, temperature,
alcohols, ethyl; use, Canada, 3105975 3101788, 3101826, 3101895, 3102335, 3102384, 3104238; ultrasonic nebulization, properties,
allergies; IV catheters, 3101842 3102424, 3102692, 3102864, 3102874, 3102889, 3106032
azithromycin, comparison, doxycycline; chlamydia 3102984, 3103752, 3104041, 3104059, 3104198, ribavirin; toxicity, hospital personnel, guidelines,
infections therapy, 3101983 3104199, 3104931, 3104956, 3105052, 3105140, 3105266
ccoonstmreatciecpst;i vegsu;i delseilneecst,i on3,1 0r2e0v8i2e w, 3103288 33110056255752, 3105345, 3105477, 3106011, 3106045, sa3l1m0e0te6r5o1l xinafoate; asthma therapy, overview,
di3s1o0p0y6r4a1m ide; overdose, toxicity, heart arrest, Adrveearctsieo nsd rug reactions, see Drugs, adverse soplrvoednutsc;t ioenx,t ra3c1t0io2n3 94s ystem, microparticle
doxycycline, comparison, azithromycin; chlamydia Advertising steroids, cortico-; asthma, pediatrics, review,
infections therapy, 3101983 alcohols, ethyl; abuse, mass media, review, 3105695; asthma therapy, pharmacology, review,
drug abuse; developmental patterns of 3105259 3102175; asthma therapy, review, 3100365;
siunrvvoelyv,e me3n1t0,2 35s5u;r veyl,o ng3 1t0e1r6m8 2p;r evHeonltoino,n Israel, an3a1l0ge6s5i3c6s and antipyretics; OTC, South Africa, tlooxnigc-ittye,r m gluasuec, omtaox,i ci3t1y,0 36o6st5e;o povrso soirsa,l , 3a1s0t3h6ma6,8 ;
p3r1o0g2r3a6m1s , 3101692; predictor, crime recidivism, cofsamleset iccsl;a imcsl,a im3s1,0 29te0s3ts , 3104299; regulation, suosvpeernvsiieown,s ; 31v0is2c0o7si9t y, lecithin effects, 3105594
drug utilization; India, 3102958 costs; Wal-Mart, 3104801 sympathomimetic agents; asthma therapy, dosage
eltechvoionnntyorlr agceeessptttrriaedvlie;o l,ec fofncitocrmaacbcyie,n patttioivxoein c,i tiym,gp elsa3tn1to0sd5,e5 n4et2;o xicity, ddre3uv1ge0sl5;o 9p7iq1un agl itcyo unotfr ileisf;e, d3r1u0g2s8, 88e thics, industry, teptrrhbeeudrtiaacpltyii,no en;a, s tt3ohxm1ia0c,6i t4y63,6 1;0o 0ve2cro7dn9ot sien,u outso picnaelb,u li3z1a0t0i0on9 6
satisfaction, 3101354 drugs, over-the-counter; laws, Netherlands, Aesculus hippocastanum; folk medicine;
methylprednisolone; pain therapy, sickle cell 3104172 constituents, toxicity, 3104020
anemia, 3105485 history; packaging, Hamlin’s Wizard Oil, 3105924 Africa
morphine; toxicity, high dose, 3105431 industry, pharmaceutical; guidelines, 3105301; acquired immunodeficiency syndrome;
Mycobacterium avium-intracellulare infection; quality assurance, EEC directives, 3100461 epidemiology health care economics, 3106493
therapy, HIV infections, 3103090 medicine; France, White Mustard, Racahout des advertising; drugs, ethics, industry, 3105971
pain; therapy. 3106324 Arabes, history, 3102925 antimalarial agents; comparisons, prophylaxis,
papilloma; minccycline therapy, 3106165 new drugs; prescribing, Netherlands, 3101321 3101389
phenylpropanolamine hydrochloride; overdose, pharmacists, community; supermarket circulars, malaria; P. falciparum malaria prophylaxis,
cardiomyopathy, 3105110 3104416 3101325
1074 International Pharmaceutical Abstracts